Abegrin (etaracizumab) / AstraZeneca - LARVOL DELTA

Arming tumor-associated macrophages to inhibit cancer progression (AACR 2024) - "In the 1990s, a humanized anti-αvβ3 antibody (Etaracizumab) was developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity...Here we define an "antigen-effector cell matching" strategy that allows for maximal anti-tumor activity for various drug resistant epithelial cancers. ABT101 will enter clinical trials for patients with drug resistant lung cancer in the first quarter of 2024."

Lung Cancer • Oncology • Solid Tumor